<DOC>
	<DOCNO>NCT00448721</DOCNO>
	<brief_summary>This single-arm phase II trial perifosine renal cancer patient experience disease progression receive either sorafenib sunitinib .</brief_summary>
	<brief_title>A Phase II Trial Perifosine Following Tyrosine Kinase Inhibitor ( TKI ) - Failure Patients With Renal Cancer</brief_title>
	<detailed_description>This single-arm phase II trial assess antitumor activity measure progression free survival perifosine patient metastatic RCC progress sorafenib sunitinib . A total 48 patient enrolled trial . All subject histologically confirm metastatic RCC predominantly clear cell feature ( ≤ 50 % histologic feature ) . Patients take sorafenib sunitinib may therapy less three month prior study enrollment . Patients remain sorafenib sunitinib may continue drug current dose two week prior initiation perifosine therapy . The study consist three period : pre-treatment/screening , treatment , follow-up . Day 1 define first day perifosine therapy . Patients remain treatment phase progression toxicity . Patients see MD every 3 week 6 week define one cycle therapy . Tumor evaluation occur every 6 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients require clear cell renal cell carcinoma le 50 % histology ( papillary chromophobe oncocytic ) . There must histologic confirmation treat center either primary metastatic lesion Patients must experience disease progression RECIST criterion sorafenib sunitinib Patients must sorafenib sunitinib &gt; = 2 week prior initiation perifosine &lt; = 3 month prior enrollment Patients may sorafenib sunitinib adjuvant setting long experienced disease recurrence therapy Patients must measurable disease curable standard radiation therapy surgery Age &gt; = 18 year ECOG performance status 0 1 Patients must ability understand willingness sign write informed consent document History clinical evidence CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis , history stroke Other sorafenib sunitinib , patient may prior immunotherapy stage IV disease Patients may prior sorafenib OR sunitinib treat TKIs Patients stop sorafenib sunitinib due toxicity progress therapy allow Patients may prior antiangiogenic bevacizumab give combination either sorafenib sunitinib Prior Thalidomide IFNα allow adjuvant therapy stage IV disease Patients may prior mTOR inhibitor ( CCI779 , RAD001 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>tyrosine kinase inhibitor failure</keyword>
</DOC>